GemVax & KAEL KRX:082270KOSDAQ
젬백스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days6
Articles tracked0since Sep 11
In Q2 2026, GemVax & KAEL reported revenue of ₩22.7bn, down 9.2% year on year, and operating profit of ₩997m. GemVax & KAEL (젬백스) appeared in 0 Korean news articles and 6 DART filings over the past seven days.
GemVax & KAEL quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩22.7bn | -9.2% | ₩997m | −₩9.9bn |
| Q1 2026 | ₩18.3bn | +47.6% | −₩765m | −₩1.5bn |
| Q4 2025 derived | ₩26.2bn | +43.2% | ₩7.5bn | ₩1.6bn |
| Q3 2025 | ₩18.0bn | +41.2% | ₩723m | −₩2.5bn |
| Q2 2025 | ₩25.0bn | +47.6% | −₩1.5bn | −₩1.6bn |
| Q1 2025 | ₩12.4bn | -16.0% | −₩3.0bn | −₩8.9bn |
| Q4 2024 derived | ₩18.3bn | -0.2% | −₩8.2bn | −₩46.7bn |
| Q3 2024 | ₩12.7bn | -6.2% | −₩8.9bn | −₩8.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
GemVax & KAEL top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest GemVax & KAEL news Korean headlines
No articles yet.